Probabilistic disease progression modeling to characterize diagnostic uncertainty: Application to staging and prediction in Alzheimer's disease

Document Details

Document Type
Pub Defense Publication
Publication Date
Apr 01, 2019
Source ID
10.1016/j.neuroimage.2017.08.059

Entities

People

  • Daniel C. Alexander
  • Giovanni B. Frisoni
  • Marco Lorenzi
  • Maurizio Filippone
  • Sebastien Ourselin

Organizations

  • AXA Research Fund
  • AbbVie
  • Alzheimer's Association
  • Alzheimer's Disease Neuroimaging Initiative
  • Alzheimer's Drug Discovery Foundation
  • Biogen
  • Bristol-Myers Squibb
  • Chiron Corporation
  • Eisai
  • Eli Lilly and Company
  • Engineering and Physical Sciences Research Council
  • GE HealthCare
  • Hoffmann-La Roche
  • Innogenetics
  • Johnson & Johnson Pharmaceutical Research and Development
  • Laboratoires Servier
  • Lundbeck
  • Merck & Co.
  • Meso Scale Diagnostics (United States)
  • National Institute on Aging
  • National Institutes of Health
  • Northern California Institute for Research and Education
  • Pfizer
  • Takeda Pharmaceutical Company